Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 7/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 4/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50605 | 0.90 | MAPT (0.43) | FDPSFAAHCES1CES2MEN1 | |
| SCHEMBL7691929 | 0.90 | MAPT (0.43) | FDPSFAAHCES1CES2MEN1 | |
| SCHEMBL27989310 | 0.76 | — | — | |
| SCHEMBL8373096 | 0.76 | CA2 (0.44) | CA2CA1DNM1FDPSTSHR | |
| SCHEMBL27411193 | 0.74 | DNM1 (0.36) | CA2CA1DNM1FDPSTSHR | |
| SCHEMBL7626563 | 0.72 | DNM1 (0.39) | CA2CA1DNM1FDPSTSHR | |
| SCHEMBL22161805 | 0.72 | FDPS (0.40) | CA2CA1DNM1FDPSTSHR | |
| SCHEMBL622107 | 0.71 | — | — | |
| SCHEMBL23010963 | 0.70 | DNM1 (0.38) | CA2CA1DNM1FDPSTSHR | |
| SCHEMBL21888898 | 0.70 | DNM1 (0.38) | CA2CA1DNM1FDPSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009121033-A2 | SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | CA2 3571/4885CA1 3563/4885DNM1 1357/4885 |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | CA2 3571/4885CA1 3563/4885DNM1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.